Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.22
GLAXF's Cash to Debt is ranked higher than
51% of the 910 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.48 vs. GLAXF: 0.22 )
GLAXF' s 10-Year Cash to Debt Range
Min: 0.02   Max: No Debt
Current: 0.22

Equity to Asset 0.13
GLAXF's Equity to Asset is ranked lower than
53% of the 823 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.59 vs. GLAXF: 0.13 )
GLAXF' s 10-Year Equity to Asset Range
Min: 0.05   Max: 0.4
Current: 0.13

0.05
0.4
Interest Coverage 9.68
GLAXF's Interest Coverage is ranked higher than
57% of the 550 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 104.14 vs. GLAXF: 9.68 )
GLAXF' s 10-Year Interest Coverage Range
Min: 0.81   Max: 28.06
Current: 9.68

0.81
28.06
F-Score: 6
Z-Score: 2.13
M-Score: -2.52
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 22.54
GLAXF's Operating margin (%) is ranked higher than
92% of the 861 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 10.67 vs. GLAXF: 22.54 )
GLAXF' s 10-Year Operating margin (%) Range
Min: 1.68   Max: 36.94
Current: 22.54

1.68
36.94
Net-margin (%) 17.63
GLAXF's Net-margin (%) is ranked higher than
91% of the 861 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.48 vs. GLAXF: 17.63 )
GLAXF' s 10-Year Net-margin (%) Range
Min: 5.76   Max: 23.94
Current: 17.63

5.76
23.94
ROE (%) 68.04
GLAXF's ROE (%) is ranked higher than
99% of the 882 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.84 vs. GLAXF: 68.04 )
GLAXF' s 10-Year ROE (%) Range
Min: 17.3   Max: 244.21
Current: 68.04

17.3
244.21
ROA (%) 10.35
GLAXF's ROA (%) is ranked higher than
91% of the 914 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.19 vs. GLAXF: 10.35 )
GLAXF' s 10-Year ROA (%) Range
Min: 3.84   Max: 26.32
Current: 10.35

3.84
26.32
ROC (Joel Greenblatt) (%) 58.14
GLAXF's ROC (Joel Greenblatt) (%) is ranked higher than
95% of the 908 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 15.66 vs. GLAXF: 58.14 )
GLAXF' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 5.44   Max: 141.62
Current: 58.14

5.44
141.62
Revenue Growth (3Y)(%) -0.90
GLAXF's Revenue Growth (3Y)(%) is ranked higher than
62% of the 743 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.60 vs. GLAXF: -0.90 )
GLAXF' s 10-Year Revenue Growth (3Y)(%) Range
Min: -1.5   Max: 15.3
Current: -0.9

-1.5
15.3
EBITDA Growth (3Y)(%) 17.30
GLAXF's EBITDA Growth (3Y)(%) is ranked higher than
83% of the 703 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.10 vs. GLAXF: 17.30 )
GLAXF' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -11.8   Max: 17.3
Current: 17.3

-11.8
17.3
EPS Growth (3Y)(%) 51.40
GLAXF's EPS Growth (3Y)(%) is ranked higher than
95% of the 675 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.70 vs. GLAXF: 51.40 )
GLAXF' s 10-Year EPS Growth (3Y)(%) Range
Min: -30.2   Max: 51.4
Current: 51.4

-30.2
51.4
» GLAXF's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with GLAXF

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 16.20
GLAXF's P/E(ttm) is ranked higher than
92% of the 949 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 44.00 vs. GLAXF: 16.20 )
GLAXF' s 10-Year P/E(ttm) Range
Min: 10.16   Max: 40.41
Current: 16.2

10.16
40.41
P/B 13.19
GLAXF's P/B is ranked higher than
51% of the 949 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.53 vs. GLAXF: 13.19 )
GLAXF' s 10-Year P/B Range
Min: 5.48   Max: 14.14
Current: 13.19

5.48
14.14
P/S 2.86
GLAXF's P/S is ranked higher than
76% of the 949 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.89 vs. GLAXF: 2.86 )
GLAXF' s 10-Year P/S Range
Min: 1.94   Max: 4.9
Current: 2.86

1.94
4.9
PFCF 19.24
GLAXF's PFCF is ranked higher than
94% of the 949 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9999.00 vs. GLAXF: 19.24 )
GLAXF' s 10-Year PFCF Range
Min: 8.21   Max: 41.33
Current: 19.24

8.21
41.33
EV-to-EBIT 15.34
GLAXF's EV-to-EBIT is ranked higher than
89% of the 949 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 33.22 vs. GLAXF: 15.34 )
GLAXF' s 10-Year EV-to-EBIT Range
Min: 7.7   Max: 240.2
Current: 15.34

7.7
240.2
PEG 6.79
GLAXF's PEG is ranked higher than
84% of the 949 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9999.00 vs. GLAXF: 6.79 )
GLAXF' s 10-Year PEG Range
Min: 0.3   Max: 99.36
Current: 6.79

0.3
99.36
Shiller P/E 15.92
GLAXF's Shiller P/E is ranked higher than
95% of the 949 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 165.76 vs. GLAXF: 15.92 )
GLAXF' s 10-Year Shiller P/E Range
Min: 10.93   Max: 21.15
Current: 15.92

10.93
21.15
Current Ratio 0.97
GLAXF's Current Ratio is ranked lower than
51% of the 893 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.41 vs. GLAXF: 0.97 )
GLAXF' s 10-Year Current Ratio Range
Min: 0.97   Max: 1.78
Current: 0.97

0.97
1.78
Quick Ratio 0.69
GLAXF's Quick Ratio is ranked lower than
52% of the 892 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.81 vs. GLAXF: 0.69 )
GLAXF' s 10-Year Quick Ratio Range
Min: 0.68   Max: 1.42
Current: 0.69

0.68
1.42

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 6.13
GLAXF's Dividend Yield is ranked higher than
99% of the 519 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.35 vs. GLAXF: 6.13 )
GLAXF' s 10-Year Dividend Yield Range
Min: 2.72   Max: 5.91
Current: 6.13

2.72
5.91
Dividend Payout 0.93
GLAXF's Dividend Payout is ranked higher than
99% of the 949 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.30 vs. GLAXF: 0.93 )
GLAXF' s 10-Year Dividend Payout Range
Min: 0.38   Max: 4.69
Current: 0.93

0.38
4.69
Dividend growth (3y) 6.40
GLAXF's Dividend growth (3y) is ranked higher than
82% of the 380 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.20 vs. GLAXF: 6.40 )
GLAXF' s 10-Year Dividend growth (3y) Range
Min: -12.6   Max: 20.8
Current: 6.4

-12.6
20.8
Yield on cost (5-Year) 8.36
GLAXF's Yield on cost (5-Year) is ranked higher than
97% of the 528 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.47 vs. GLAXF: 8.36 )
GLAXF' s 10-Year Yield on cost (5-Year) Range
Min: 3.73   Max: 8.1
Current: 8.36

3.73
8.1
Share Buyback Rate 1.40
GLAXF's Share Buyback Rate is ranked higher than
90% of the 621 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -1.30 vs. GLAXF: 1.40 )
GLAXF' s 10-Year Share Buyback Rate Range
Min: 3.6   Max: -20
Current: 1.4

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 1.41
GLAXF's Price/DCF (Projected) is ranked higher than
91% of the 949 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9.02 vs. GLAXF: 1.41 )
GLAXF' s 10-Year Price/DCF (Projected) Range
Min: 0.82   Max: 4.16
Current: 1.41

0.82
4.16
Price/Median PS Value 0.98
GLAXF's Price/Median PS Value is ranked higher than
83% of the 949 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.29 vs. GLAXF: 0.98 )
GLAXF' s 10-Year Price/Median PS Value Range
Min: 0.69   Max: 2.59
Current: 0.98

0.69
2.59
Earnings Yield (Greenblatt) 6.50
GLAXF's Earnings Yield (Greenblatt) is ranked higher than
88% of the 907 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.20 vs. GLAXF: 6.50 )
GLAXF' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.4   Max: 12.9
Current: 6.5

0.4
12.9
Forward Rate of Return (Yacktman) 7.55
GLAXF's Forward Rate of Return (Yacktman) is ranked higher than
76% of the 497 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.05 vs. GLAXF: 7.55 )
GLAXF' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 4.1   Max: 53.2
Current: 7.55

4.1
53.2

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:JNJ, PFE, RHHBY, NVS, ABT » details
Traded in other countries:GSK.UK, GSK.USA, GS7A.Germany, GS7.Germany, GSK N.Mexico, GSK.Argentina, GSK.Switzerland,
GlaxoSmithKline PLC incorporated in United Kingdom. The Company creates, discoveres, develops, manufactures and markets pharmaceutical products including vaccines, over-the-counter (OTC) medicines and health-related consumer products. The Company's principal pharmaceutical products include medicines in the following therapeutic areas: respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, oncology and emesis, dermatology, rare diseases, immuno-inflammation, vaccines and HIV. The Company is a science-led global healthcare company that researches and develops a broad range of innovative products in three primary areas of pharmaceuticals, vaccines and consumer healthcare. Its Pharmaceuticals business develops and makes medicines to treat a broad range of acute and chronic diseases. Its portfolio is made up of both patent-protected and off patent medicines. Its products include treatment for Infectious Diseases, Cancer, Epilepsy, Heart Disease, Asthma and Chronic obstructive pulmonary disease, and HIV/AIDS. Its Vaccine business has approximately 900 million doses distributed to 170 countries in 2012. It produces paediatric and adult vaccines to prevent a range of infectious diseases including: Hepatitis A and B, Diphtheria, Tetanus and Whooping cough, Measles, Mumps and Rubella, Polio, Typhoid, Influenza, Bacterial Meningitis. The consumer healthcare business, markets consumer health products based on scientific innovation. Its products main categories are: Oral care, Nutritional, Total wellness, and Skin health. Its barands include Sensodyne, Panadol and Horlicks. Its drinks brands are Lucozade and Ribena. The Oral Care brands, alli and Abreva.
» More Articles for GLAXF

Headlines

Articles On GuruFocus.com
tester Dec 18 2014 
Weekly 3-Year Low Highlights: RDS.B, GSK, WPZ, CLR Dec 14 2014 
Pfizer Spreading Its Wings Into A New Domain Of Life Sciences Dec 09 2014 
The Top 5 European Stocks Held During Q3 Nov 25 2014 
Jeff Auxier Buys Berkshire Hathaway in Third Quarter Nov 18 2014 
Irving Kahn Starts New Position In GlaxoSmithKline Nov 13 2014 
Irving Kahn Buys Stake in GlaxoSmithKline During Q3 2014 Nov 12 2014 
Kahn Brothers' Third Quarter Numbers Nov 07 2014 
Tweedy Browne Global Value Fund's Top Picks for Q3 Oct 21 2014 
Diamond Hill Capital Comments on GlaxoSmithKline PLC Oct 17 2014 

More From Other Websites
Ebola crisis could last through 2015 as marks year since outbreak-expert-TRFN Dec 24 2014
Ex-B&Q Chief In Frame For Top Whitehall Role Dec 22 2014
FDA approves BioCryst's intravenous flu drug Dec 22 2014
Drugmaker Hikma on lookout for acquisitions Dec 21 2014
GSK Ebola vaccine trial seen moving to wider phase in February Dec 19 2014
Avon bribed Chinese officials with Gucci bags Dec 18 2014
The year the sun set on the Bric economies Dec 18 2014
The sun is setting on the emerging market miracle Dec 18 2014
Five predictions for Britain's battered supermarket industry in 2015 Dec 18 2014
REUTERS AMERICA NEWS PLAN FOR THURSDAY DEC 18 Dec 18 2014
BUZZ-Agenus Inc: Partner GSK's shingles vaccine meets goal Dec 18 2014
GSK shareholders approve asset swap deal with Novartis Dec 18 2014
GlaxoSmithKline shingles vaccine hits goal in major study Dec 18 2014
Specialist City anti-corruption unit to be set up after scandals Dec 17 2014
Global business leaders join fight against ebola at UN conference Dec 11 2014
Merck suspends trial of Ebola vaccine Dec 11 2014
McLaren speeds up GSK with racetrack expertise Dec 10 2014
FTSE 100 movers: Ashtead boosted by first-half profits, gas companies still struggling Dec 10 2014
Top Executives Quit Woodford Funds Venture Dec 09 2014
Sukuk for vaccine fund ushers Islamic finance into ethical sphere Dec 07 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK